Free press releases distribution network?

Agency / Source: The Scott Partnership

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Novozymes Biopharma Secures Albucult® Supply Agreement for Use in Medical Devices - Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, has signed a supply agreement for albucult, recombinant albumin with one of the world’s leading manufacturers of medical disposables for open heart surgery
Novozymes Biopharma Secures Albucult® Supply Agreement for Use in Medical Devices

 

PRZOOM - /newswire/ - Holmes Chapel, Cheshire, United Kingdom, 2010/06/24 - Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, has signed a supply agreement for albucult, recombinant albumin with one of the world’s leading manufacturers of medical disposables for open heart surgery.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, has signed a supply agreement for albucult, recombinant albumin with one of the world’s leading manufacturers of medical disposables for open heart surgery. This agreement will result in the launch of the first Class III medical device containing albucult.

Novozymes Biopharma has supplied animal-free, recombinant human albumin to this leading manufacturer for over 10 years and this new agreement solidifies the already successful partnership between the two companies. Derived from Novozymes Biopharma’s proprietary yeast expression technology, albucult delivers unprecedented performance and quality benefits to medical applications including device coating, sealants, and cell therapy applications.

Class III devices are highly regulated and used in ‘high risk’ applications such as pacemakers and heart valves. The use of albucult within such medical devices offers a range of unique advantages including sustainability of supply, GMP compliance and improved biocompatibility. albucult also offers batch-to-batch consistency which can significantly reduce lot testing burdens for clients.

“Novozymes Biopharma is pleased to consolidate its position in the medical device market with the signing of this long-term agreement”, says Dermot Pearson, Marketing Director, Novozymes Biopharma. “This continued partnership demonstrates Novozymes’ strength and extensive understanding of manufacturing, regulatory and global supply, making the company an ideal partner to work with. It is a great achievement for albucult to be used for the first time within a Class III medical device product and is a real testament to the quality and innovation of the products that we are developing.”

About Novozymes
Novozymes (biopharma.novozymes.com) is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow’s industrial biosolutions, improving our customers' business and the use of our planet's resources.

With over 700 products used in 130 countries, Novozymes’ bioinnovations improve industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s ever-changing marketplace.

Novozymes’ natural solutions enhance and promote everything from removing trans fats in cooking, to advancing biofuels to power the world tomorrow. Our never-ending exploration of nature’s potential is evidenced by over 6,000 patents, showing what is possible when nature and technology join forces.

Our 5,000+ employees working in research, production and sales around the world are committed to shaping business today and our world tomorrow.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: The Scott Partnership

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Novozymes Biopharma Secures Albucult® Supply Agreement for Use in Medical Devices

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Scottpr.com 
+44 1477 539539
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any The Scott Partnership securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From The Scott Partnership / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  JobsWare.com

Visit  NAKIVO, Inc.

Visit  MagLar, Inc.







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today